In contrast to other studies showing that ILC-mediated intestinal pathology requires dual blockade of IL-17 and IFN-γ to abrogate disease (Buonocore et al., 2010), in TRUC IBD IL-17A blockade alone reversed disease. Here, IL17A is linked to inflammatory bowel disease.